Glenmark becomes first to launch biosimilar of popular anti‐diabetic drug, Liraglutide, in India

Lirafit™ will sharply lower the daily cost of therapy by around 70% to around Rs 100; making the drug more accessible to a larger number of patients with type 2 diabetes mellitus in the country

New Delhi: Glenmark Pharmaceuticals has launched a biosimilar of the popular anti‐diabetic drug, Liraglutide, for the first time in India.
The drug is being marketed under the brand name Lirafit™ following the approval from the Drug Controller General of India (DCGI). Priced at around INR 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription.
Liraglutide belongs to the class of glucagon‐like peptide 1 receptor agonist (GLP‐1 RA) drugs, which increase glucose‐dependent insulin secretion and decrease in appropriate glucagon secretion.12,13 It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union.
“Glenmark is proud to introduce Lirafit™, a novel and affordable biosimilar of the drug liraglutide, for the first time in India. Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity.1‐5 Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus. With this launch, we have now ventured into the injectable anti‐diabetic market taking another significant stride in the diabetes therapy space,” remarked Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals.
Liraglutide and its role in the treatment of type 2 diabetes Liraglutide has a proven efficacy in improving glycemic control in patients with type 2 diabetes mellitus. Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24‐week period have demonstrated Lirafit™ to be effective, safe and well‐tolerated. The trials also revealed non‐inferior efficacy and a safety profile with that of the reference liraglutide.
Additional benefits of liraglutide include effectively lowering glycemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus2‐5,13,14. GLP‐1 RA class of drugs and their mechanism of action GLP‐1 RA (Glucagon‐like peptide‐1 receptor agonists) are a group of drugs used in the treatment of type 2 diabetes.13 GLP‐1 RAs are very effective in lowering blood sugar levels. Several trials have demonstrated that GLP‐1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio‐renal outcomes beyond their blood glucose‐lowering effects in type 2 diabetes mellitus patients.
Their mechanism of action involves the release of insulin, in the presence of elevated glucose concentrations, thus decreasing glucagon secretion. GLP‐1 RAs are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co‐morbidities, like established atherosclerotic cardiovascular disease and obesity.